An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada

C Rotstein MD FRCPC1, Michel Laverdière MD2, Anne Marciniak MD3, Farzad Ali BPharm MSc4

ORIGINAL ARTICLE

BACKGROUND: Invasive aspergillosis (IA) is a serious fungal infection that affects immunocompromised patients. The Global Comparative Aspergillosis study demonstrated that voriconazole, a new broad-spectrum triazole, had better responses and improved survival compared with conventional amphotericin B deoxycholate (CAB) and other licensed antifungal therapy (OLAT) for the treatment of definite or probable aspergillosis.

OBJECTIVES: To compare costs and outcomes of voriconazole and CAB for the treatment of definite or probable aspergillosis in Canada.

METHODS: A cost-consequence decision tree model was designed to reflect the treatment pathways used in clinical practice when using voriconazole or CAB as primary therapy for IA. Therapy included initial treatment with either voriconazole or CAB and then switched to an OLAT in the event of an inadequate response, severe toxicity or intolerance. The principal data source used was the Global Comparative Aspergillosis study.

RESULTS: The total cost of voriconazole when compared with CAB as initial therapy for IA was $38,319 versus $42,495 per patient, respectively, representing a 9.8% cost reduction for each patient treated with voriconazole. The higher mean cost in the CAB arm was primarily due to the high proportion of patients (73.7%) who were switched to an OLAT due to severe side effects or an inadequate response. Treating with voriconazole was a dominant strategy. The number of patients that had to be treated with voriconazole instead of CAB to save one additional life was eight.

CONCLUSIONS: Voriconazole as primary treatment for IA increased the chances of successful treatment, improved survival and may represent a potential cost saving strategy in Canada.

Key Words: Amphotericin B; Aspergillosis; Costs; Cost-effectiveness; Voriconazole

Invasive aspergillosis (IA) is a serious fungal infection that affects immunocompromised patients, particularly those with hematological malignancies and those who have undergone hematopoietic stem cell or solid organ transplantation (1). Studies in the United States (US) indicate that the incidence of serious fungal infections has increased significantly in hospitalized patients over the past 20 years (2,3). A 4.5-fold annual increase was estimated for IA incidence between 1996 and 1999 (3). In Canada, the annual incidence of invasive fungal infection was estimated to be between 3.54 and 6.64
Voriconazole, a new broad-spectrum triazole, has been shown to have potent activity against Aspergillus clinical isolates (17). The Global Comparative Aspergillosis (GCA) study, a randomized multicentre trial, compared voriconazole treatment with CAB treatment in 277 immunocompromised patients with definite or probable IA (18). Other licensed antifungal therapies (OLAT) were allowed if the initial therapy failed or if the patient was intolerant to the initial therapy. In the present study, OLAT included L-AMB, amphotericin B lipid complex (ABLC) and oral itraconazole. At the end of 12 weeks, 52.8% of voriconazole-treated patients exhibited complete or partial responses compared with 31.6% of CAB-treated patients (95% CI for the difference between groups of 10.4% to 32.9%). Survival was greatly improved in the voriconazole group (70.8% versus 57.9% for CAB; hazard ratio 0.59; 95% CI 0.40 to 0.88) and significantly fewer adverse events (P=0.02), including nephrotoxicity (P<0.001), were reported.

Although the clinical efficacy of voriconazole has been demonstrated, it remains unclear whether its use is economically advantageous in Canada. A recent economic evaluation of the costs of IA treatment in immunocompromised patients in the US (based on data from the GCA study) indicated that initiating treatment with voriconazole in comparison with CAB offers an average cost savings of US$3,594 for every treated patient (19). Thus, the objective of the present study was to compare the costs and outcomes of voriconazole and CAB with OLAT for the treatment of definite or probable aspergillosis in Canada using a cost-consequence model based on clinical outcomes from the GCA study. The analysis was conducted from the perspective of the Canadian health care system. Since IA is predominantly treated in hospital settings, only direct costs of inpatient and outpatient hospital care were considered.

**METHODS**

**Decision analytical model**

A cost-consequence model was used to compare the cost outcomes of initiating voriconazole versus CAB as primary therapy for proven or probable aspergillosis. The model was based on a decision tree designed to reflect the treatment pathways relevant for clinical practice. The decision tree is presented in Figure 1.

Treatment was initiated with either voriconazole (eg, 6 mg/kg intravenously (IV) twice a day on day 1, followed by 4 mg/kg IV twice a day for at least seven days, at which time patients could switch to oral voriconazole 200 mg twice a day) or CAB (eg, 1.0 mg/kg to 1.5 mg/kg once a day IV). In the event of an inadequate response or severe toxicity, patients were switched from initial therapy to an OLAT. The OLAT administered during the study that were considered in the model included CAB, L-AMB, oral itraconazole, a combination of CAB and oral itraconazole or a combination of L-AMB and oral itraconazole. Similarly, patients on voriconazole could be switched to an OLAT. Switches were classified as ‘early switch’ or ‘no early switch’. An ‘early switch’ was classified as a switch occurring four days or fewer after the initiation of treatment and was primarily due to infusion-related toxicity. Within the ‘no early switch’ group, there were five further classifications: no switch, no-response switch, renal toxicity switch, hepatotoxicity switch and switch due to other reasons (Figure 1). Progressing from IV CAB to oral itraconazole therapy or IV voriconazole to oral voriconazole therapy was not
considered to be a switch (eg, failure) provided the reason for the switch was only to change the patient from IV to oral therapy.

Thus, there were six alternative treatment pathways in the voriconazole and CAB treatment arms (Figure 1). The number of patients expected to follow each treatment pathway is indicated in Figure 1.

For each of the treatment pathways in the model, there were two possible outcomes at the end of the 12 weeks: success or failure (Figure 1). Based on the GCA study, the cost-consequence model in the present study used two measures of success: treatment success and patient survival at week 12. Treatment success was defined as the complete or partial resolution of signs and symptoms of aspergillosis, and the requirement of patient survival at 12 weeks. Thus, patients that experienced treatment success constituted a subgroup of the patients that survived to 12 weeks.

Model inputs
Clinical outcomes and resource use: The GCA study (18), a randomized trial of 277 patients with definite or probable aspergillosis, was the main source of data for the model. The study protocol was developed under the aegis of an international steering committee that included the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer to ensure that the management of aspergillosis during the study reflected current clinical practice. The primary objective of the GCA study was to demonstrate the noninferiority of voriconazole at week 12 in a modified intent-to-treat population as assessed by an independent and blinded data review committee. This population was defined as having received at least one dose of randomized treatment and had a definite or probable diagnosis of IA as assessed by the data review committee. Patients were allowed to switch to an OLAT in the event of an inadequate response or severe toxicity.

All patients in the trial were followed for 12 weeks, whether they continued to take their initial randomized treatment or switched to an OLAT. The reason for switch was classified according to the reason given by the investigator. Renal toxicity prompting a switch from initial study medication to an OLAT was decided by the treating physician in the GCA study. Moreover, discontinuation of the study drugs was recommended in the GCA study protocol in cases of severe adverse renal or hepatic events, an increase in the serum creatinine level to double the baseline value or more than 265 µmol/L (3.0 mg/dL) if the baseline value was higher than 133 µmol/L (1.5 mg/dL), or an increase in aminotransferase levels to more than five times the upper limit of normal or 10 times the upper limit of normal if the baseline was more than two times the upper limit of normal (18). The GCA study provided the following data to populate the model: clinical success rates, morbidity and mortality data, treatment duration, OLAT use for each patient and resource use for the two treatment arms. Information was also derived from the GCA trial for days of IV and oral therapy, hospital length of stay and time spent on initial therapy before switching to an OLAT.

In the few instances where there was insufficient information in the GCA study, an independent expert panel was consulted (Canadian Voriconazole Advisory Board for the Pharmacoeconomic Model Validation, see appendix for a list of participants). Fifteen Canadian experts (12 physicians and three hospital pharmacists) with extensive experience in managing invasive fungal infections were surveyed. They were asked for resource use information regarding patients with aspergillosis who were successfully treated using monotherapy with each of the following drugs: CAB, L-AMB and oral itraconazole.

Cost of voriconazole in the treatment of invasive aspergillosis

![Figure 1] Decision tree for the treatment of invasive aspergillosis with voriconazole or conventional amphotericin B. Switch: switch to other licensed antifungal therapy (AF) following inadequate response or severe toxicity; Success: the complete or partial resolution of signs and symptoms of aspergillosis; Failure: inadequate response, severe toxicity or death. Numbers indicate how many patients followed each treatment pathway.

The information provided by the expert panel was used to assess the duration of antifungal switch therapy with OLAT, the management of toxicities and supportive treatment. This information was also used to screen and monitor the infection. Screening data included chest x-ray, computed tomography scan, bronchoalveolar lavage and nonblood fungal cultures. Monitoring data included complete blood counts and liver and renal function tests.

Because there were differences between European and North American switch patterns in the GCA trial, the expert panel recommended using North American GCA data for the Canadian cost model. The distribution of OLAT days was determined by dividing the total number of days patients spent on each OLAT by the total number of days patients spent on all OLAT. Based on North American switch patterns, patients initially assigned to CAB who switched treatment (73.7% of all CAB patients) spent 45.7% of all OLAT days on L-AMB (n=524 total days), 31% of all OLAT days on itraconazole (n=350 total days) and 14.1% of all OLAT days on voriconazole (n=350 total days). Only 28.5% of patients initially assigned to voriconazole switched to an OLAT. Voriconazole OLAT days were primarily composed of L-AMB (64.8%; n=278 total days), itraconazole (15.4%; n=66 total days) or CAB (12.1%; n=52 total days).

Unit costs: All costs are reported in 2002 Canadian dollars. Costs were obtained from different Canadian provinces because costs did not vary significantly between provinces. Thus, costs were derived from different provincial sources to ensure generalizability across Canada. Further, cost information was obtained from sources that were considered by the expert panel to be the best sources of cost data. Thus, the cost of voriconazole was obtained from Pfizer Canada, the cost of CAB was obtained from the Ontario Drug Benefit List (20) and the cost of L-AMB was obtained from Fujisawa Canada, Inc. The cost for these agents in mg/kg was based on a 65 kg patient. The expert panel recom-
The cost calculations in the model were performed as follows: Model calculations

Assumptions The model assumed a full course of treatment for those patients remaining on one of the two initial randomized treatments. The model considered a switch as a failure of initial therapy. Therefore, patients who switched were assumed to have received initial therapy up to the time they were switched. These patients were also assumed to have started therapy over with an OLAT, with all of the clinical, resource and cost sequelae associated with the new therapy. Because information on OLAT switch treatment success rates was limited, the same costs were used for all patients within a switch category. The model assessed a single episode of antifungal therapy side effects and treatment for neutropenic infection, prophylaxis, monitoring and treatment of antifungal therapy side effects and treatment for neutropenic patients (eg, assumed only 40% of IA cohort).

Model calculations

1. The total cost per patient for voriconazole (Cvor) and CAB (CCAB) treatment pathways with no switch to OLAT was calculated by adding the total costs per patient of the following: screening for fungal infections, antifungal therapy (eg, IV and step-down oral), hospitalization/care (eg, inpatient and outpatient), diagnosis/monitoring of infection, prophylaxis, monitoring and treatment of antifungal therapy side effects and treatment for neutropenic patients (eg, assumed only 40% of IA cohort).

2. The total cost per patient for voriconazole and CAB treatment pathways with a switch to an OLAT (eg, C_CAB/early tox for a switch due to early toxicity; C_CAB/no response for a switch due to no response; C_CAB/renal tox for a switch due to renal toxicity; C_CAB/hepatol tox for a switch due to hepatotoxicity; C_CAB/other switch for a switch due to other reasons) was calculated by adding the cost per patient of the initial voriconazole or CAB therapy to the total cost per patient of the switch therapy.

3. To calculate the total average cost per patient for voriconazole and CAB arms, the total cost per patient with no switch (C_CAB/no switch) and each switch treatment pathway (C_CAB/early tox, C_CAB/no response, C_CAB/renal tox, C_CAB/hepatol tox, C_CAB/other switch) weighted according to the proportion of patients in each pathway were added together.

4. The incremental cost per successfully treated case and per life saved was calculated using the difference in the average cost per patient for voriconazole and CAB arms divided by the difference in the probability of treatment success and/or survival in each respective arm.

5. The number needed to treat (NNT) in order to save one additional life was calculated based on the inverse difference in mortality between voriconazole and CAB treatment arms.

Sensitivity analysis Because treatment outcomes, resource use and costs are inherently associated with a degree of variability, a sensitivity analysis was carried out in order to assess how changes in key input variables would affect the final output of the model. These variables included treatment success rates, hospital length of stay, hospital costs, treatment switches and antifungal costs. Nine different scenarios were tested:

- CAB total hospital length of stay for nonswitch patients was increased from 18 to 23 days (to equal the voriconazole total length of stay);
- CAB ICU bed days for nonswitch patients were increased from four to five days;
- Cost per day for a general ward bed was increased by 50%;
- Cost per day for an ICU bed was decreased by 50%;
- CAB time to switch was increased from 16 to 26 days (to equal the voriconazole time to switch);
- Voriconazole time to switch was decreased from 26 to 16 days (to equal the CAB time to switch);
RESULTS

Resources used and implicated costs in Canadian dollars are listed in Table 1, while hospital lengths of stay are shown in Table 2. Hospitalization costs were $441 per day for a general ward bed and $1,458 per day for an ICU bed. Among patients who did not switch therapies, the mean length of hospital stay was longer for voriconazole patients than for CAB patients (23 versus 18 days, respectively) (Table 2). This observation was mainly due to the higher mortality rate of CAB patients (42.1% versus 29.2% for voriconazole). However, because more CAB patients experienced toxicities and switched therapies (leading to additional days in hospital), overall, the weighted mean length of stay for each treatment arm used was almost identical (30.3 days for CAB versus 29.6 days for voriconazole).

The costs for the voriconazole and CAB treatment arms as generated by the model are presented in Table 2. Voriconazole offered a cost savings of $4,176 compared with CAB as the initial therapy for invasive aspergillosis (average total cost per patient of $38,319 versus $42,495, respectively). The weighted total cost of initiating treatment with voriconazole was influenced predominantly by patients who did not switch treatment (71.5%), while the weighted total cost of initiating treatment with CAB was influenced primarily by patients who switched treatment due to major renal toxicity (30.8%), early acute toxicity (19.5%) and nonresponse (15%).

Major renal toxicity was the major source of extra cost in the CAB arm. Major renal toxicity was defined based on the decision of the treating physician to stop CAB and prescribe an OALT following signs of renal toxicity. Because switching increased the hospital length of stay, the cost of treating a patient who switched treatment due to major renal toxicity was $60,779 compared with a cost of $17,480 for a patient who remained on CAB treatment. In comparison, switches due to

### TABLE 1

<table>
<thead>
<tr>
<th>Resource</th>
<th>Number of units used per patient over course of treatment</th>
<th>Total cost per patient over course of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungal therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAB – 1 mg/kg/day IV</td>
<td>21</td>
<td>$1,568.70*</td>
</tr>
<tr>
<td>L-AMB – 5 mg/kg/day IV</td>
<td>21</td>
<td>$30,870.00*</td>
</tr>
<tr>
<td>Itra – 400 mg oral/day (step down from IV CAB)</td>
<td>7</td>
<td>$186.26</td>
</tr>
<tr>
<td>Itra – 400 mg oral/day</td>
<td>64</td>
<td>$1,702.91</td>
</tr>
<tr>
<td>Vor – 12 mg/kg/day IV</td>
<td>1</td>
<td>$560.00*</td>
</tr>
<tr>
<td>Vor – 8 mg/kg/day IV</td>
<td>13</td>
<td>$5,460.00*</td>
</tr>
<tr>
<td>Vor – 400 mg oral/day</td>
<td>50</td>
<td>$4,750.00</td>
</tr>
<tr>
<td><strong>Hospitalization/outpatient care – additional days due to aspergillosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAB, Vor – Inpatient intensive care unit days</td>
<td>4</td>
<td>$5,832.00</td>
</tr>
<tr>
<td>CAB – Other inpatient days</td>
<td>14</td>
<td>$6,174.00</td>
</tr>
<tr>
<td>Vor – Other inpatient days</td>
<td>19</td>
<td>$8,379.00</td>
</tr>
<tr>
<td>CAB – Outpatient day hospital visits</td>
<td>3</td>
<td>$771.68</td>
</tr>
<tr>
<td>Vor – Outpatient day hospital visits</td>
<td>4</td>
<td>$777.68</td>
</tr>
<tr>
<td>CAB, Vor – Outpatient physician visit 25 min</td>
<td>2</td>
<td>$224.70</td>
</tr>
<tr>
<td>L-AMB, Itra switch – Intensive care unit days</td>
<td>6</td>
<td>$8,748.00</td>
</tr>
<tr>
<td>L-AMB, Itra switch – Outpatient physician visit 25 min</td>
<td>2</td>
<td>$224.70</td>
</tr>
<tr>
<td>L-AMB, Itra switch – Other inpatient days</td>
<td>17</td>
<td>$7,497.00</td>
</tr>
<tr>
<td>L-AMB, Itra switch – Outpatient physician visit 25 min</td>
<td>4</td>
<td>$777.68</td>
</tr>
<tr>
<td><strong>Prophylaxis and treatment of antifungal therapy side effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-AMB – Acetaminophen 1g/day oral</td>
<td>21</td>
<td>$24.15</td>
</tr>
<tr>
<td>L-AMB – Diphenhydramine 50 mg/day IV</td>
<td>21</td>
<td>$24.15</td>
</tr>
<tr>
<td>CAB, L-AMB – Meperidine 50 mg/day IV</td>
<td>21</td>
<td>$14.49</td>
</tr>
<tr>
<td>Granulocyte colony-stimulating factor</td>
<td>14</td>
<td>$1,380.74</td>
</tr>
<tr>
<td>300 µg/day (neutropenic patients only)</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Meropenem 1.0 g every 8 h (neutropenic patients only)</td>
<td>42</td>
<td>$794.30</td>
</tr>
<tr>
<td>L-AMB, Itra switch – Outpatient physician visit 25 min</td>
<td>2</td>
<td>$224.70</td>
</tr>
<tr>
<td><strong>Diagnosis and monitoring</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest x-ray</td>
<td>6</td>
<td>$133.50</td>
</tr>
<tr>
<td>Computed tomography scan</td>
<td>2</td>
<td>$131.20</td>
</tr>
<tr>
<td>Bronchoalveolar lavage</td>
<td>1</td>
<td>$134.85</td>
</tr>
<tr>
<td>Fungal culture (nonblood)</td>
<td>1</td>
<td>$20.00</td>
</tr>
<tr>
<td><strong>Monitoring for side effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete blood count</td>
<td>6</td>
<td>$96.00</td>
</tr>
<tr>
<td>Renal function test</td>
<td>6</td>
<td>$186.00</td>
</tr>
<tr>
<td>Liver function test</td>
<td>6</td>
<td>$30.00</td>
</tr>
</tbody>
</table>

*Cost based on a 65 kg patient. †Assumed only 40% of cohort neutropenic, thus a weighted cost per patient for granulocyte colony-stimulating factor and meropenem is used in the model. All costs are listed in Canadian dollars. CAB Conventional amphotericin B; Itra Itraconazole; L-AMB Liposomal amphotericin B (AmBisome, USA); Vor Voriconazole.
renal toxicity were absent in the voriconazole arm and, therefore, no extra costs were incurred.

Cost-effectiveness analyses demonstrated that voriconazole was both more effective and less costly than CAB. Indeed, the probabilities of a successful treatment outcome and survival were higher for voriconazole. The total cost per treatment success and the total cost per survivor were lower for patients treated with voriconazole than for those treated with CAB. The incremental costs per successfully treated case and per life saved with voriconazole were negative. Thus, voriconazole dominated CAB as a treatment option (Table 4).

The absolute reduction in mortality risk for the voriconazole arm over the CAB arm was 12.9% (Table 4), and the NNT, which is the reciprocal of the absolute risk reduction, was 8 (25). Thus, treating eight patients with voriconazole instead of CAB would save one additional life.

**Sensitivity analysis**

The nine scenarios tested in the sensitivity analysis demonstrated that the dominance of voriconazole over CAB was robust (Figure 2). In the base case, voriconazole use resulted in cost savings of $4,176 per patient when compared with CAB. The model was sensitive to changes in hospital costs: a 50% increase in the cost per day of a general ward bed resulted in cost savings of $3,817 for voriconazole.

Sensitivity analysis

The nine scenarios tested in the sensitivity analysis demonstrated that the dominance of voriconazole over CAB was robust (Table 4). The model was sensitive to the time to switch: increasing the CAB time to switch and decreasing the voriconazole time to switch improved the cost savings for voriconazole to $9,068 per patient. The model was also sensitive to the time to switch: increasing the CAB time to switch and decreasing the voriconazole time to switch improved the cost savings for voriconazole to $9,068 and $6,853, respectively. A 50% reduction in the cost of L-AMB was the only scenario in which voriconazole no longer dominated CAB as a treatment option (Table 4).

**DISCUSSION**

Poor clinical outcomes and increased resource use can negate the anticipated cost savings of a drug with a low acquisition price, while improved clinical outcomes and reduced resource use can offset cost increases related to higher acquisition costs. Therefore, comparisons of the relative costs of antifungal agents should be predicated on total associated costs, including the cost of hospital stay, cost of treating drug-related adverse events, the cost switching or adding therapies and drug acquisition costs. The reasons for switching from the initial therapy (eg, voriconazole or CAB) included a switch due to an infusion-related toxicity, lack of response (eg, efficacy), renal toxicity, hepatotoxicity and other reasons (26).

CAB has traditionally been used because of its broad-spectrum activity, clinical efficacy and low acquisition cost. However, the total cost of treatment with this antifungal is greatly increased by the costs involved in preventing and treating adverse events (27) (particularly renal toxicity [15]), and the necessity to switch patients to an OLAT because of toxicity or lack of efficacy (8). In the present study, almost 31% of CAB-treated patients switched to another antifungal, mainly due to renal toxicity at an incremental cost of $42,495 per patient. Similarly, in a US study (15), the incremental cost for patients experiencing CAB-related nephrotoxicity reported in 30% of cases was US$30,000 per patient.

The incidence of renal- and infusion-related toxicity is generally lower with L-AMB or ABLC than with CAB (12). An economic analysis of empirical antifungal therapy in persistently febrile neutropenic patients investigated to what degree savings associated with reduced nephrotoxicity could offset higher acquisition costs of the liposomal formulation (28). Despite a lower incidence of nephrotoxicity in the L-AMB group (19% for L-AMB versus 34% for CAB), overall hospital costs were significantly higher with L-AMB than with CAB (US$48,962 versus US$43,183, respectively). This was due to the substantially higher drug acquisition costs associated with L-AMB (US$188.40 for L-AMB versus US$16.60 for CAB per 50 mg vial). Only at an acquisition cost of US$72.00 would L-AMB become less costly than CAB. Although these findings cannot be directly applied to the treatment of confirmed or suspected IA, they suggest that L-AMB may not be economically attractive as first-line therapy in this indication.

In addition, a recent pharmacoeconomic impact model of voriconazole versus L-AMB in the treatment of systemic fungal infections in immunocompromised patients projected that modest shifts in prescription patterns from L-AMB to voriconazole could lead to annual savings in antifungal drug
costs in the range of US$20,846 to US$62,537 for an institutionalized population of 100 patients (29). The projected savings were attributable to lower wholesale acquisition costs of voriconazole compared with L-AMB and the availability of an oral formulation of voriconazole.

The average cost saving of $4,176 per patient in the present study compares well with an estimated cost saving of $6,000 (approximately US$3,594) in another study (19) comparing treatment costs of voriconazole versus CAB in the US based on outcomes of the GCA study. As in the present analysis, the US study found that the main cost drivers in the CAB treatment arm were costs associated with switches to an OLAT due to renal toxicity and early toxicity (19). A substantial part of these additional costs stemmed from the high acquisition costs of the L-AMB (19). Another economic analysis based on outcomes of the GCA trial evaluated the cost of antifungal medication for patients randomized to voriconazole and CAB followed by an OLAT treatment (30). Overall drug costs per patient in this analysis were US$772 lower for patients randomized to initial treatment with voriconazole compared with CAB. This was due to the higher proportion of patients in the CAB arm switching to an OLAT treatment (80% versus 36% in the voriconazole arm) and the relatively high cost of OLAT drugs (30). The economic advantage of voriconazole was made more obvious when total antifungal drug costs per successfully treated patient were compared (US$10,305 for the voriconazole arm versus US$19,667 for the CAB arm) (30).

According to the cost-consequence model used in the present study, the use of voriconazole as primary therapy for IA instead of the current gold standard (CAB, followed by any other approved antifungal therapy) would generate substantial economic benefits in Canada. Treatment with voriconazole resulted in an average cost savings of $4,176 per patient relative to CAB. The cost per successfully treated patient was $72,604 and $134,569 for voriconazole and CAB, respectively, while the cost per life saved was $54,123 and $73,395 for voriconazole and CAB, respectively. Moreover, success and survival rates were significantly higher when treatment was initiated with voriconazole. The markedly higher survival rate in voriconazole-treated patients yielded a NNT value of eight for treatment with voriconazole compared with usual therapy with CAB. The NNT value of eight indicates that if eight patients are treated with voriconazole instead of CAB, one additional death will be averted within a 12-week timeframe. For comparison, a recent meta-analysis of the antifungal effectiveness and tolerability of amphotericin B formulations in the treatment of systemic fungal infections estimated that, overall, 31 patients need to be treated with lipid formulations of amphotericin B instead of CAB in order to prevent one death (10).

There are some limitations to the present study. First, the structure of the decision tree model described in the analysis assumes a simplified switch pattern. Although the model appropriately reflects treatment patterns and health resource use data from the clinical trial, it is a simplification of current medical practice. In addition, based on GCA study data, the average duration of antifungal therapy was lower for CAB patients than voriconazole patients because patients in the CAB arm died sooner. This tended to bias the results against voriconazole.

Second, model resource use was not broken down by success and failure of each type of switch because the numbers were too small. Large variability between these small numbers could have distorted the results. To minimize potential distortions, outcomes were aggregated at a success versus failure level for all patients in each treatment group, and costs were aggregated for each type of switch by treatment group.

Third, in order to simplify our model, we assumed that L-AMB was the sole lipid formulation of amphotericin B employed as an OLAT. In fact, in the GCA study, L-AMB was used as an OLAT two-thirds of the time, while ABLC was administered one-third of the time. The use of ABLC as an alternative to L-AMB was not considered in the economic evaluation. While ABLC is less expensive than L-AMB, it may be somewhat less efficacious for the treatment of IA (31). However, this issue was addressed in the sensitivity analysis where a 50% reduction in the cost of L-AMB (eg, a cost comparable to that of ABLC) was considered. The sensitivity analysis for a 50% reduction in the cost of L-AMB demonstrated that voriconazole remained almost cost-neutral when compared with CAB therapy followed by an OLAT, indicating that there is a wide margin within which the ratio of cost-to-consequence of using voriconazole remains favourable. Therefore, even if ABLC and L-AMB were used one-third and two-thirds of the time, respectively, it would have had little impact on the outcome of the model, which favoured voriconazole.

Fourth, caspofungin acetate was not considered as one of the OLAT antifungals because it was not available at the time of the GCA study. Further, there are no studies comparing the efficacy and safety of voriconazole with that of caspofungin acetate in the treatment of IA. Finally, the model assumed a switch from IV voriconazole to the oral formulation by day 15 of therapy. The duration of IV voriconazole was recommended by the expert panel of advisors based on the anticipated duration of IV therapy reflective of clinical practice in Canada. This recommendation was in keeping with the mean duration of IV voriconazole in the GCA study (15 days, Pfizer internal document, unpublished data) for patients receiving a full course of voriconazole therapy. The median duration of IV voriconazole therapy (10 days) reported by Herbrecht et al (18) included both patients receiving a full course of voriconazole therapy and switching to an OLAT. Should the therapeutic sequence be altered by increasing the duration of IV voriconazole therapy, the voriconazole drug acquisition costs would certainly be inflated, thus reducing any potential cost reductions.
associated with its use. However, it is unlikely that the mean length of IV voriconazole would extend beyond 14 days. In contrast, a reduction in the duration of IV voriconazole therapy would simultaneously reduce drug costs.

In summary, the cost-consequence model for IA suggests that a voriconazole treatment regimen is both more clinically and cost effective in Canada than CAB treatment. Substantial economic benefits may arise from the use of voriconazole as primary therapy for IA. These benefits would be achieved despite the choice of best available therapy (CAB followed by other approved antifungal therapies, including L-AMB, ABLC and oral itraconazole). Voriconazole increases the chances of successfully treating IA, improves patient survival and may potentially save costs in Canada.

APPENDIX: The following individuals were members of the Canadian Voriconazole Advisory Board for the Pharmacoeconomic Model Validation who participated in the meeting held in Ottawa, September 5, 2002: Dr Upton Allen, The Hospital for Sick Children, Toronto, Ontario; Dr Eric Bow, Health Sciences Centre, Winnipeg, Manitoba; Ms Sylvie Carle, Royal Victoria Hospital, Montreal, Quebec; Dr Ronal Feld, Princess Margaret Hospital, Toronto, Ontario; Dr Gary Garber, Ottawa General Hospital, Ottawa, Ontario; Dr Alfred Gin, Health Sciences Centre, Winnipeg, Manitoba; Dr David Haase, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia; Dr Arul Humar, Toronto General Hospital, Toronto, Ontario; Dr Michel Lavender, Hospital Maisonneuve-Rosemont, Montreal, Quebec; Dr Rene Pelletier, Hospital Hotel Dieu de Quebec, Quebec City, Quebec; Dr Peter Phillips, Vancouver General Hospital and St Paul’s Hospital, Vancouver, British Columbia; Dr Coleman Rotstein, Hamilton Health Sciences, Hamilton, Ontario; Dr Stephen Sanche, Royal University Hospital, Saskatoon, Saskatchewan; Dr Stephen Shafran, University of Alberta Hospital, Edmonton, Alberta; and Mr Gary Wong, Toronto General Hospital, Toronto, Ontario.

ACKNOWLEDGEMENTS: The authors wish to thank investigators and significant contributors; particularly, Michael Ortiz, RTI Health Solutions. This study was made possible by a grant from Pfizer Canada Inc. BioMedCom Consultants Inc., Montreal, Canada, assisted in the presentation of the data.

REFERENCES